The French High Health Authority (HAS) has given the green light to the “without delay” resumption of vaccination with AstraZeneca, but recommends reserve it for 55-year-olds and more, in a notice published this Friday.
This restriction was decided because the serious and rare bleeding disorders that had led to the suspension of this vaccine in several European countries were only observed in people under 55 years of age, the French health authority said. There have been three cases in France, the statement added. In addition, this Friday vaccination has been resumed in Germany and Italy.
Spain will expand it
The Secretary of Public Health of the Generalitat, Josep Maria Argimon, has stated today that this Friday or Saturday the Ministry of Health will approve raising the age limit of the AstraZeneca vaccine to vaccinate those over 55 years in Spain with doses from this laboratory. This decision has already been adopted in several countries of the European environment, which were based on new studies to extend the age of inoculation of the same. However, in Spain the debate was interrupted by the appearance of the suspicious blood clots, for which it had to be postponed.
Argimon’s statements have been produced in an interview on TV3 collected by Europa Press, when asked if the Ministry of Health is considering starting to vaccinate this group even though the Ministry of Health does not increase the age limit: «I would not advance events, because today or tomorrow the cap will be broken ».
Scandinavian countries continue to study it
On the other hand, Denmark, Sweden and Norway They said on Friday they needed more time to decide whether to use the AstraZeneca vaccine despite the EMA arguing yesterday that the benefits outweighed the risks.
“We need time to get to the bottom of this,” Soren Brostrom, head of the Danish Health Authority, told reporters on Friday. “On the basis of a precautionary principle, we are continuing with our suspension, because we need to understand this better, in order to be able to say with certainty that we recommend this vaccine,” added Brostrom.
Health authorities in the three Scandinavian countries said they would decide on the use of the AstraZeneca vaccine next week. Norway has so far reported five cases in which vaccine recipients were admitted later in hospital with a combination of blood clots, bleeding and low platelets, one of which passed away.
A sixth person, who also received the vaccine, died from a brain hemorrhage in combination with low platelet counts. These cases are rare, but very serious. We cannot rule out that these cases may be related to the AstraZeneca vaccine, ”said the Norwegian Medicines Agency.
What’s more, Finland has suspended this Friday vaccination with AstraZeneca while investigating two cases of thrombi between inoculated with said solution. It has asked its citizens “at least a week” while the circumstances causing the two clots are clarified.
George is Digismak’s reported cum editor with 13 years of experience in Journalism